

**SOME PHARMACOLOGICAL AND PHYTOCHEMICAL  
STUDIES OF *CLITORIA TERNATEA* EXTRACTS**

**KAMILLA LINGGAM**

**UNIVERSITI SAINS MALAYSIA  
2012**

**SOME PHARMACOLOGICAL AND PHYTOCHEMICAL STUDIES  
OF *CLITORIA TERNATEA* EXTRACTS**

**by**

**KAMILLA LINGGAM**

**Thesis submitted in fulfillment of the requirements for the degree of  
Master of Science**

**January 2012**

*To my Lord Sri Krishna*  
*and*  
*dearest family members*

## ACKNOWLEDGEMENT

First and foremost, I would like to offer my humble obeisance to my Lord Sri Krishna and spiritual grandmaster HDG Bhaktivedanta Swami Srila Praphupada. Their blessings and mercy have made my voyage a successful one. I would like to express my greatest gratitude from the bottom of my heart to my supervisor Assoc. Prof. Surash Ramanathan for his conscientious and constructive criticism, benevolence and generosity which gave me the strength, knowledge and creativity to complete my research and compile the thesis.

My deepest appreciation to my co-supervisors Prof. Sharif Mahsufi Mansor and Dr. Sasidharan Sreenivasan for their thoughtful and continuous guidance, comments and motivation throughout the research. I would also like to extend my special appreciation to Dr. Vikneswaran Murugaiyah for his assistance and guidance.

I would also like to take this opportunity to thank all the lab assistants and staffs of Center for Drug Research for their assistance during the research. Very special thanks to Mr. Mohd. Hilman Sulaiman and Mr. Zulkeflee Ismail from Center for Drug Research and Mr. Johari, Mr. Patchamuthu, Ms. Shantini and Puan Nurul from School of Biological Sciences for their technical supports and assistance. I would also like to express my special appreciation to my dearest colleagues Nalini Krishnan, Amala Rajoo, Suhanya Parthasarathy, Ranjeev Hari, Juzaili Azizi and Azadeh Sabetghadam for their sound judgements, technical assistances and continuous encouragement throughout the research.

My special gratitude to the Institute of Postgraduate Studies (IPS) for granting me the USM fellowship which supported me during my research. Also a special recognition to USM Short Term Grant (304/CDADAH/638128) and USM RU Grant (1001/CDADAH/813041) which supported the research.

It has been a great fortune and blessing to have parents and family members who gave me encouragement, support and strength throughout the research period. Finally, I would like to apologize, in advance, for any errors that may occur in the text.

## TABLE OF CONTENTS

|  | <b>Page</b>                         |
|--|-------------------------------------|
| <b>ACKNOWLEDGEMENT</b>                                       | iii                                 |
| <b>LIST OF TABLES</b>  | xii                                 |
| <b>LIST OF FIGURES</b>                                       | xiv                                 |
| <b>LIST OF SYMBOLS AND ABBREVIATIONS</b>                     | xvii                                |
| <b>LIST OF APPENDICES</b>                                    | xxv                                 |
| <b>LIST OF PUBLICATIONS</b>                                  | xxvi                                |
| <b>ABSTRAK</b>   | xxvii                               |
| <b>ABSTRACT</b>  | xxix                                |
| <br>   |                                     |
| <b>CHAPTER 1</b> .....                                       | <b>Error! Bookmark not defined.</b> |
| <b>1.0 INTRODUCTION</b> .....                                | <b>Error! Bookmark not defined.</b> |
| 1.1 Objectives .....   | <b>Error! Bookmark not defined.</b> |
| <br>   |                                     |
| <b>CHAPTER 2</b> .....                                       | <b>Error! Bookmark not defined.</b> |
| <b>2.0 LITERATURE REVIEW</b> .....                           | <b>Error! Bookmark not defined.</b> |
| 2.1 Herbal medicine .....                                    | <b>Error! Bookmark not defined.</b> |
| 2.2 Plant introduction .....                                 | <b>Error! Bookmark not defined.</b> |
| 2.2.1 <i>Clitoria ternatea</i> .....                         | <b>Error! Bookmark not defined.</b> |
| 2.2.2 Botany and pharmacognosy of <i>C. ternatea</i> .....   | <b>Error! Bookmark not defined.</b> |
| 2.2.3 Traditional uses of <i>C. ternatea</i> .....           | <b>Error! Bookmark not defined.</b> |
| 2.2.4 Other uses .....                                       | <b>Error! Bookmark not defined.</b> |
| 2.2.5 Pharmacological activities of <i>C. ternatea</i> ..... | <b>Error! Bookmark not defined.</b> |
| 2.3 Quality control of extracts .....                        | <b>Error! Bookmark not defined.</b> |
| 2.4 Phytochemistry .....                                     | <b>Error! Bookmark not defined.</b> |
| 2.4.1 Sample selection, collection and identification .....  | <b>Error! Bookmark not defined.</b> |
| 2.4.2 Extraction of plant constituents .....                 | <b>Error! Bookmark not defined.</b> |

|           |  |                                     |
|-----------|--|-------------------------------------|
| 2.4.2 (a) | Maceration extraction .....                            | <b>Error! Bookmark not defined.</b> |
| 2.4.2 (b) | Types of solvent .....                                 | <b>Error! Bookmark not defined.</b> |
| 2.4.3     | Purification of plant constituents .....               | <b>Error! Bookmark not defined.</b> |
| 2.4.4     | Separation and identification of plant constituents .. | <b>Error! Bookmark not defined.</b> |
| 2.4.4 (a) | Thin Layer Chromatography (TLC)                        | <b>Error! Bookmark not defined.</b> |
| 2.4.4 (b) | Gas Chromatography-Mass Spectroscopy (GC-MS) .....     | <b>Error! Bookmark not defined.</b> |
| 2.4.4 (c) | Fourier Transform InfraRed Spectroscopy (FTIR).....    | <b>Error! Bookmark not defined.</b> |
| 2.5       | Toxicity evaluation .....                              | <b>Error! Bookmark not defined.</b> |
| 2.5.1     | Acute oral toxicity .....                              | <b>Error! Bookmark not defined.</b> |
| 2.6       | Antioxidant .....                                      | <b>Error! Bookmark not defined.</b> |
| 2.6.1     | Oxidation.....   | <b>Error! Bookmark not defined.</b> |
| 2.6.2     | Free radicals .....                                    | <b>Error! Bookmark not defined.</b> |
| 2.6.3     | Antioxidant and its mechanism.....                     | <b>Error! Bookmark not defined.</b> |
| 2.6.4     | Importance of antioxidant .....                        | <b>Error! Bookmark not defined.</b> |
| 2.6.5     | <i>In vitro</i> antioxidant assays.....                | <b>Error! Bookmark not defined.</b> |
| 2.6.5 (a) | 2,2-Diphenyl-2-picrylhydrazyl (DPPH) Assay ....        | <b>Error! Bookmark not defined.</b> |
| 2.6.5 (b) | Ferric reducing antioxidant power (FRAP)....           | <b>Error! Bookmark not defined.</b> |
| 2.6.5 (c) | Total phenolic content .....                           | <b>Error! Bookmark not defined.</b> |
| 2.6.5 (d) | Total flavonoid content.....                           | <b>Error! Bookmark not defined.</b> |
| 2.7       | Antinociceptive.....                                   | <b>Error! Bookmark not defined.</b> |
| 2.7.1     | Pain.....  | <b>Error! Bookmark not defined.</b> |
| 2.7.2     | Classification of pain.....                            | <b>Error! Bookmark not defined.</b> |
| 2.7.3     | Analgesic drugs.....                                   | <b>Error! Bookmark not defined.</b> |
| 2.7.3 (a) | Opioid analgesics.....                                 | <b>Error! Bookmark not defined.</b> |
| 2.7.3 (b) | Non-opioid analgesics .....                            | <b>Error! Bookmark not defined.</b> |
| 2.7.4     | Testing for antinociceptive properties.....            | <b>Error! Bookmark not defined.</b> |

|   |                                     |
|---|-------------------------------------|
| 2.7.4 (a) Hot plate test.....   | <b>Error! Bookmark not defined.</b> |
| 2.7.4 (b) Tail flick test.....  | <b>Error! Bookmark not defined.</b> |
| 2.7.4 (c) Formalin test.....  | <b>Error! Bookmark not defined.</b> |
| 2.7.5 Natural products as analgesic drugs.....  | <b>Error! Bookmark not defined.</b> |
| 2.8 Antimicrobial.....  | <b>Error! Bookmark not defined.</b> |
| 2.8.1 Antimicrobial resistance .....  | <b>Error! Bookmark not defined.</b> |
| 2.8.2 Need for antimicrobial agents from medicinal plants....   | <b>Error! Bookmark not defined.</b> |
| 2.8.3 <i>Aspergillus</i> species and Aspergillosis .....  | <b>Error! Bookmark not defined.</b> |
| 2.8.4 <i>In vitro</i> antimicrobial susceptibility testing.....   | <b>Error! Bookmark not defined.</b> |
| 2.8.4 (a) Agar diffusion methods .....  | <b>Error! Bookmark not defined.</b> |
| 2.8.4 (b) Dilution method.....  | <b>Error! Bookmark not defined.</b> |
| 2.8.4 (c) Bioautography .....   | <b>Error! Bookmark not defined.</b> |
| 2.8.5 <i>In vivo</i> antifungal activity against <i>Aspergillus niger</i>                                   | <b>Error! Bookmark not defined.</b> |
| 2.8.5 (a) Histopathology.....   | <b>Error! Bookmark not defined.</b> |
| 2.8.5 (b) Detection of galactomannan.....   | <b>Error! Bookmark not defined.</b> |
| <b>CHAPTER 3 .....</b>  | <b>Error! Bookmark not defined.</b> |
| <b>3.0 MATERIALS AND METHODS.....</b>   | <b>Error! Bookmark not defined.</b> |
| 3.1 Chemicals and reagent.....  | <b>Error! Bookmark not defined.</b> |
| 3.2 Instruments used .....  | <b>Error! Bookmark not defined.</b> |
| 3.3 Plant material.....   | <b>Error! Bookmark not defined.</b> |
| 3.4 Extraction of plant material .....  | <b>Error! Bookmark not defined.</b> |
| 3.5 Quality control analysis of <i>C. ternatea</i> using Gas Chromatography-Mass Spectrometry (GC-MS) ..... | <b>Error! Bookmark not defined.</b> |
| 3.5.1 GC-MS polar column.....   | <b>Error! Bookmark not defined.</b> |
| 3.5.2 GC-MS non-polar column.....   | <b>Error! Bookmark not defined.</b> |
| 3.6 Qualitative phytochemical screening of <i>C. ternatea</i> methanolic crude extracts.....                | <b>Error! Bookmark not defined.</b> |
| 3.6.1 Braemer's test for tannins .....  | <b>Error! Bookmark not defined.</b> |



- 3.6.2 Test for phlobatannins.....**Error! Bookmark not defined.**
- 3.6.3 Test for steroids.....**Error! Bookmark not defined.**
- 3.6.4 Salkowski test for terpenoids .....**Error! Bookmark not defined.**
- 3.6.5 Liebermann-Burchardt test for steroids and terpenoids .**Error! Bookmark not defined.**
- 3.6.6 Alkaloid.....**Error! Bookmark not defined.**
- 3.6.7 KOH test for anthraquinones .....**Error! Bookmark not defined.**
- 3.6.8 Shinoda test for flavonoids .....**Error! Bookmark not defined.**
- 3.6.9 Frothing test for saponin .....**Error! Bookmark not defined.**
- 3.6.10 Keller-killiani test for cardiac glycosides**Error! Bookmark not defined.**
- 3.6.11 Volatile oil.....**Error! Bookmark not defined.**
- 3.7 Toxicity assay .....**Error! Bookmark not defined.**
  - 3.7.1 Acute oral toxicity assay .....**Error! Bookmark not defined.**
    - 3.7.1 (a) Experimental animals .....**Error! Bookmark not defined.**
    - 3.7.1 (b) Sighting study.....**Error! Bookmark not defined.**
    - 3.7.1 (c) Acute oral main study.....**Error! Bookmark not defined.**
    - 3.7.1 (d) Histopathological studies .....**Error! Bookmark not defined.**
    - 3.7.1 (e) Statistical analysis.....**Error! Bookmark not defined.**
- 3.8 Antioxidant activities of *C. ternatea* plant parts .....**Error! Bookmark not defined.**
  - 3.8.1 DPPH free radical scavenging activity .....**Error! Bookmark not defined.**
  - 3.8.2 Ferric reducing antioxidant power (FRAP) assay ....**Error! Bookmark not defined.**
  - 3.8.3 Determination of total phenolic content....**Error! Bookmark not defined.**
  - 3.8.4 Determination of total flavonoid content ..**Error! Bookmark not defined.**
  - 3.8.5 High-Performance Thin Layer Chromatography (HPTLC) profile of DPPH activity .....**Error! Bookmark not defined.**
  - 3.8.6 Statistical analysis .....**Error! Bookmark not defined.**
- 3.9 Antimicrobial activities of *C. ternatea* plant parts .....**Error! Bookmark not defined.**
  - 3.9.1 Test microorganisms and growth media ...**Error! Bookmark not defined.**

- 3.9.2 Agar disc diffusion assay for bacteria, yeast and mold cultures ..... **Error! Bookmark not defined.**
- 3.9.3 Determination of minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MBC) for bacteria and yeast cultures... **Error! Bookmark not defined.**
- 3.9.4 Determination of minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) for mold cultures ..... **Error! Bookmark not defined.**
- 3.9.5 Statistical analysis ..... **Error! Bookmark not defined.**
- 3.9.6 Scanning Electron Microscopy (SEM) study of *C. ternatea* leaf extract against *Aspergillus niger*..... **Error! Bookmark not defined.**
- 3.10 Antinociceptive activities of *C. ternatea* leaf and root methanolic extracts  
..... **Error! Bookmark not defined.**
- 3.10.1 Preparation of plant extracts and reference drugs ..**Error! Bookmark not defined.**
- 3.10.2 Experimental animals..... **Error! Bookmark not defined.**
- 3.10.3 Assessment of antinociceptive activity ... **Error! Bookmark not defined.**
- 3.10.3 (a) Formalin test ..... **Error! Bookmark not defined.**
- 3.10.3 (b) Hot plate test..... **Error! Bookmark not defined.**
- 3.10.3 (c) Tail flick test..... **Error! Bookmark not defined.**
- 3.10.4 Statistical analysis ..... **Error! Bookmark not defined.**
- 3.11 *In vivo* study of *C. ternatea* leaf extracts against murine Aspergillosis . **Error! Bookmark not defined.**
- 3.11.1 Preparation of plant extracts and reference drugs ..**Error! Bookmark not defined.**
- 3.11.2 Organism ..... **Error! Bookmark not defined.**
- 3.11.3 Experimental animals..... **Error! Bookmark not defined.**
- 3.11.4 Induction of an immunosuppressed state **Error! Bookmark not defined.**
- 3.11.5 Experimental aspergillosis ..... **Error! Bookmark not defined.**
- 3.11.6 Extract and standard drug treatments..... **Error! Bookmark not defined.**
- 3.11.7 Cultures from organ homogenates ..... **Error! Bookmark not defined.**
- 3.11.8 Histopathology ..... **Error! Bookmark not defined.**

- 3.11.9 Galactomannan assay ..... **Error! Bookmark not defined.**
- 3.11.10 Statistical analysis ..... **Error! Bookmark not defined.**
- 3.12 Identification and characterization of anti-*Aspergillus* bioactive(s)  
compound from *C. ternatea* leaf extract..... **Error! Bookmark not defined.**
  - 3.12.1 Fractionation of *C. ternatea* leaf extract . **Error! Bookmark not defined.**
  - 3.12.2 Bioactivity of *C. ternatea* leaf fractions.. **Error! Bookmark not defined.**
    - 3.12.2 (a) Agar disc diffusion assay of *C. ternatea* leaf fractions ..... **Error! Bookmark not defined.**
    - 3.12.2 (b) Agar dilution assay of *C. ternatea* leaf fractions **Error! Bookmark not defined.**
    - 3.12.2 (c) Bioautography ..... **Error! Bookmark not defined.**
  - 3.12.3 Identification of bioactive(s) band ..... **Error! Bookmark not defined.**
  - 3.12.4 Purification of antifungal active band..... **Error! Bookmark not defined.**
  - 3.12.5 Bioactivity of active band ..... **Error! Bookmark not defined.**
    - 3.12.5 (a) Agar disc diffusion assay..... **Error! Bookmark not defined.**
    - 3.12.5 (b) Agar dilution assay ..... **Error! Bookmark not defined.**
    - 3.12.5 (c) Bioautography ..... **Error! Bookmark not defined.**
  - 3.12.6 Identification and characterization of active spot .. **Error! Bookmark not defined.**
    - 3.12.6 (a) Phytochemical assays ..... **Error! Bookmark not defined.**
    - 3.12.6 (b) Gas Chromatography-Mass Spectrometer (GC-MS) analysis  
using polar column ..... **Error! Bookmark not defined.**
    - 3.12.6 (c) Gas Chromatography-Mass Spectrometer (GC-MS) analysis  
using non-polar column..... **Error! Bookmark not defined.**
    - 3.12.6 (d) Fourier Transform Infrared Spectroscopy (FT-IR) ..... **Error! Bookmark not defined.**

**CHAPTER 4** ..... **Error! Bookmark not defined.**

**4.0 RESULTS**..... **Error! Bookmark not defined.**

- 4.1 Plant material ..... **Error! Bookmark not defined.**
- 4.2 Extraction of plant material..... **Error! Bookmark not defined.**
- 4.3 Quality control analysis of *C. ternatea* using Gas Chromatography-Mass Spectrometry (GC-MS) ..... **Error! Bookmark not defined.**

|        |  |                                     |
|--------|--|-------------------------------------|
| 4.4    | Qualitative phytochemical screening of <i>C. ternatea</i> methanolic crude extracts .....  | <b>Error! Bookmark not defined.</b> |
| 4.5    | Toxicity assay .....   | <b>Error! Bookmark not defined.</b> |
| 4.5.1  | Acute oral toxicity assay .....  | <b>Error! Bookmark not defined.</b> |
| 4.6    | Antioxidant assays .....   | <b>Error! Bookmark not defined.</b> |
| 4.6.1  | DPPH free radical scavenging activity .....  | <b>Error! Bookmark not defined.</b> |
| 4.6.2  | Ferric reduction activity .....  | <b>Error! Bookmark not defined.</b> |
| 4.6.3  | Total phenolic content.....  | <b>Error! Bookmark not defined.</b> |
| 4.6.4  | Total flavonoid content .....  | <b>Error! Bookmark not defined.</b> |
| 4.6.5  | High Performance Thin Layer Chromatography (HPTLC) profile of DPPH activity .....  | <b>Error! Bookmark not defined.</b> |
| 4.7    | Antimicrobial assays.....  | <b>Error! Bookmark not defined.</b> |
| 4.7.1  | Agar disc diffusion, minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC) assays..... | <b>Error! Bookmark not defined.</b> |
| 4.7.2  | Scanning Electron Microscopy (SEM) study of <i>C. ternatea</i> leaf extract against <i>Aspergillus niger</i> .....   | <b>Error! Bookmark not defined.</b> |
| 4.8    | Antinociceptive activities of <i>C. ternatea</i> leaf and root methanolic extracts .....   | <b>Error! Bookmark not defined.</b> |
| 4.8.1  | Formalin test .....  | <b>Error! Bookmark not defined.</b> |
| 4.8.2  | Hot plate test .....   | <b>Error! Bookmark not defined.</b> |
| 4.8.3  | Tail flick test .....  | <b>Error! Bookmark not defined.</b> |
| 4.9    | <i>In vivo</i> study of <i>C. ternatea</i> leaf extracts against murine Aspergillosis ...  | <b>Error! Bookmark not defined.</b> |
|        | <b>Bookmark not defined.</b>   |                                     |
| 4.9.1  | Survival of animals .....  | <b>Error! Bookmark not defined.</b> |
| 4.9.2  | Fungal burden in organs.....   | <b>Error! Bookmark not defined.</b> |
| 4.9.3  | Serum galactomannan detection .....  | <b>Error! Bookmark not defined.</b> |
| 4.9.4  | Histopathology .....   | <b>Error! Bookmark not defined.</b> |
| 4.10   | Identification and characterization of anti- <i>Aspergillus</i> bioactive(s) fraction from <i>C. ternatea</i> leaf extract .....                             | <b>Error! Bookmark not defined.</b> |
| 4.10.1 | Fractionation of <i>C. ternatea</i> leaf extract .   | <b>Error! Bookmark not defined.</b> |
| 4.10.2 | Bioactivity of <i>C. ternatea</i> leaf fractions..   | <b>Error! Bookmark not defined.</b> |

|   |                                     |
|---|-------------------------------------|
| 4.10.2 (a) Agar disc diffusion assay of <i>C. ternatea</i> leaf fractions ..... | <b>Error!</b>                       |
| <b>Bookmark not defined.</b>  |                                     |
| 4.10.2 (b) Agar dilution assay of <i>C. ternatea</i> leaf fractions             | <b>Error! Bookmark not defined.</b> |
| 4.10.2 (c) Bioautography assay of <i>C. ternatea</i> leaf fractions.....        | <b>Error!</b>                       |
| <b>Bookmark not defined.</b>  |                                     |
| 4.10.3 Identification of bioactive(s) band .....                                | <b>Error! Bookmark not defined.</b> |
| 4.10.4 Separation of antifungal active band (sp1) using preparative TLC         | <b>Error!</b>                       |
| <b>Bookmark not defined.</b>  |                                     |
| 4.10.5 Bioactivity of sp1 .....   | <b>Error! Bookmark not defined.</b> |
| 4.10.5 (a) Agar disc diffusion assay.....                                       | <b>Error! Bookmark not defined.</b> |
| 4.10.5 (b) Agar dilution assay.....   | <b>Error! Bookmark not defined.</b> |
| 4.10.5 (c) Bioautography .....  | <b>Error! Bookmark not defined.</b> |
| 4.10.6 Identification and characterization of bioactive spot (sp1) .....        | <b>Error!</b>                       |
| <b>Bookmark not defined.</b>  |                                     |
| 4.10.6 (a) Phytochemical assays .....   | <b>Error! Bookmark not defined.</b> |
| 4.10.6 (b) GC-MS Analysis .....   | <b>Error! Bookmark not defined.</b> |
| 4.10.6 (b1) Non-polar column.....   | <b>Error! Bookmark not defined.</b> |
| 4.10.6 (b2) Polar column.....   | <b>Error! Bookmark not defined.</b> |
| 4.10.6 (c) FT-IR analysis .....   | <b>Error! Bookmark not defined.</b> |
| <b>CHAPTER 5</b> .....  | <b>Error! Bookmark not defined.</b> |
| <b>5.0 DISCUSSION</b> .....   | <b>Error! Bookmark not defined.</b> |
| <b>CHAPTER 6</b> .....  | <b>Error! Bookmark not defined.</b> |
| <b>6.0 CONCLUSION</b> .....   | <b>Error! Bookmark not defined.</b> |
| <b>CHAPTER 7</b> .....  | <b>Error! Bookmark not defined.</b> |
| <b>7.0 FUTURE WORK</b> .....  | <b>Error! Bookmark not defined.</b> |

**APPENDICES**

## LIST OF TABLES

|            |   | <b>Page</b> |
|------------|---|-------------|
| Table 2.1  | Pharmacological activities of <i>C. ternatea</i> Linn. (Source: Mukherjee et al., 2008).  | 12          |
| Table 2.2  | Chemical properties of solvents.  | 19          |
| Table 2.3  | The clinical effect of the opioid receptors. (Source: Cavill & Kerr, 2003).   | 40          |
| Table 2.4  | Stimuli used in analgesic testing (Source: Vonvoigtlander, 1982).   | 44          |
| Table 4.1  | Crude extract yield after maceration extraction method.   | 92          |
| Table 4.2  | Phytochemical screening of secondary metabolites from <i>C. ternatea</i> .  | 97          |
| Table 4.3  | Mean body weight of mice after 14 days treatment with leaf extract of <i>C. ternatea</i> .  | 98          |
| Table 4.4  | Mean organ weight of mice after 14 days treatment with leaf extract of <i>C. ternatea</i> .   | 99          |
| Table 4.5  | Antioxidant properties of <i>C. ternatea</i> and known antioxidant.   | 106         |
| Table 4.6  | Total phenolic and total flavonoid content.   | 107         |
| Table 4.7  | Zone of growth inhibition exhibited by <i>C. ternatea</i> crude extracts at 100 mg/mL and reference antibiotics.                          | 114         |
| Table 4.8  | Minimum inhibition, minimum bactericidal and minimum fungicidal concentration of the <i>C. ternatea</i> crude extracts.                   | 115         |
| Table 4.9  | Effect of <i>C. ternatea</i> leaf and root extracts on the reaction time of rats in the formalin test.                                    | 121         |
| Table 4.10 | Effect of <i>C. ternatea</i> leaf and root extracts on the reaction time of rats in the hot plate test.                                   | 122         |
| Table 4.11 | Effect of <i>C. ternatea</i> leaf and root extracts on the reaction time of rats in the hot plate test after pre-treatment with naloxone. | 122         |
| Table 4.12 | Effect of <i>C. ternatea</i> leaf and root extracts on the reaction time of rats in the tail flick test.                                  | 123         |

|            |   |     |
|------------|---|-----|
| Table 4.13 | Effect of <i>C. ternatea</i> leaf and root extracts on the reaction time of rats in the tail-flick test after pre-treatment with naloxone.                                    | 123 |
| Table 4.14 | Fungal burden in spleen, kidney and lung homogenates of the infected animals killed at different time intervals post-infection.   | 126 |
| Table 4.15 | Yields of fractions fractionated from <i>C. ternatea</i> leaf extract. Values are presented as mean±SEM (n=3) with different letters are significantly different at p < 0.05. | 132 |
| Table 4.16 | Antifungal activity of <i>C. ternatea</i> leaf fractions against <i>A. niger</i> .  | 133 |
| Table 4.17 | The inhibition concentration 50 (IC <sub>50</sub> ) of <i>C. ternatea</i> leaf fractions against <i>A. niger</i> .  | 134 |
| Table 4.18 | Identification of sp1 from butanol fraction developed through EFGW eluent system.   | 137 |
| Table 4.19 | Yields of antifungal active band sp1.   | 138 |
| Table 4.20 | Antifungal activity of <i>C. ternatea</i> leaf fractions and sp1 against <i>A.niger</i> .   | 139 |
| Table 4.21 | The inhibition concentration 50 (IC <sub>50</sub> ) of <i>C. ternatea</i> leaf fractions and sp1 against <i>A. niger</i> .  | 140 |
| Table 4.22 | Phytochemical screening of sp1.   | 142 |
| Table 4.23 | Components of sp1 identified through non-polar column.  | 143 |
| Table 4.24 | Components of sp1 identified through polar column.  | 145 |

## LIST OF FIGURES

|             |   | <b>Page</b> |
|-------------|---|-------------|
| Figure 2.1  | <i>C. ternatea</i> Linn plant.  | 9           |
| Figure 2.2  | <i>C. ternatea</i> Linn flower in blue colour.  | 9           |
| Figure 4.1  | <i>C. ternatea</i> herbarium.   | 91          |
| Figure 4.2  | GC-MS fingerprints of <i>C. ternatea</i> crude extracts measured by polar column. A: leaf; B: stem; C: flower; D: seed; E: root.  | 94          |
| Figure 4.3  | GC-MS fingerprints of <i>C. ternatea</i> crude extracts measured by non-polar column. A: leaf; B: stem; C: flower; D: seed; E: root   | 96          |
| Figure 4.4  | The light microscope histological examination of kidney tissues in control and 2000 mg/kg of <i>C. ternatea</i> leaf extract treated mice   | 100         |
| Figure 4.5  | The light microscope histological examination of lung tissues in control and 2000 mg/kg of <i>C. ternatea</i> leaf extract treated mice.  | 101         |
| Figure 4.6  | The light microscope histological examination of spleen tissues in control and 2000 mg/kg of <i>C. ternatea</i> leaf extract treated mice.  | 102         |
| Figure 4.7  | The light microscope histological examination of liver tissues in control and 2000 mg/kg of <i>C. ternatea</i> leaf extract treated mice.   | 103         |
| Figure 4.8  | The light microscope histological examination of heart tissues in control and 2000 mg/kg of <i>C. ternatea</i> leaf extract treated mice.   | 104         |
| Figure 4.9  | Free radical scavenging activity of <i>C. ternatea</i> extracts measured by DPPH assay. Results are expressed as mean±S.D. (n=3).   | 105         |
| Figure 4.10 | The HPTLC profile of <i>C. ternatea</i> extracts and antioxidant standards developed using ethyl acetate-methanol-water (100:13.5:10). The track lanes have been designated as Lf: leaf; St: stem; Fl: flower; Sd: seed; Rt: root; KG: kaempferol-3-glucoside; KR: kaempferol-3-rutinoside; K: kaempferol; Q: quercetin; R: rutin; Ct: catechin; CA: caffeic acid. Figure 4.10A and B illustrate the separated substances visualised at 254nm and 365nm. Figure 4.10C discloses the DPPH active yellow spots against purple | 109         |



background after spraying with 0.2% DPPH reagent.

- Figure 4.11 Chromatographic profiles of kaempferol-3-glucoside, leaf, stem and flower extract. Kaempferol-3-glucoside designated as K3G was identified in leaf, stem and flower extract. 110
- Figure 4.12 Chromatographic profiles of kaempferol-3-rutinoside, leaf, stem and flower extract. Kaempferol-3-rutinoside designated as K3R was identified in leaf, stem and flower extract. 111
- Figure 4.13 Scanning electron micrographs of *A. niger* mycelium grown on PDA with or without *C. ternatea* leaf extract. (A) Control and (B-H) collapsed hyphae treated with 0.8 mg/mL *C. ternatea* leaf extract. Distorted, flattened, and degrading hyphae are clearly visible. 117
- Figure 4.14 Scanning electron micrographs of *A. niger* conidiophores grown on PDA with or without *C. ternatea* leaf extract. (A) Control and (B-H) collapsed conidiophores treated with 0.8 mg/mL of *C. ternatea* leaf extract. Distorted and damaged conidiophores are clearly visible. 118
- Figure 4.15 Survival of *Aspergillus*-infected untreated mice and treated mice with *C. ternatea* leaf extract and Amp B. The survival of *C. ternatea* leaf and AmpB treated groups are overlapping. 124
- Figure 4.16 Galactomannan levels in untreated, leaf extract and AmpB treated *Aspergillus*-infected mice. Galactomannan level was considered negative when GMI < 0.5. 127
- Figure 4.17 Histopathology of kidneys of *Aspergillus*-infected untreated mice (i) and mice treated with *C. ternatea* leaf extract (ii) and AmpB (iii) at day 1 (plates labelled 'A'), day 3 (plates labelled 'B'), day 5 (plates labelled 'C'), day 7 (plates labelled 'D'), day 14 (plates labelled 'E'), day 21 (plates labelled 'F') and day 28 (plates labelled 'G') of treatment. 129
- Figure 4.18 Histopathology of lungs of *Aspergillus*-infected untreated mice (i) and mice treated with *C. ternatea* leaf extract (ii) and AmpB (iii) at day 1 (plates labelled 'A'), day 3 (plates labelled 'B'), day 5 (plates labelled 'C'), day 7 (plates labelled 'D'), day 14 (plates labelled 'E'), day 21 (plates labelled 'F') and day 28 (plates labelled 'G') of treatment. 131

|             |   |     |
|-------------|---|-----|
| Figure 4.19 | The front view (A) and back view (B) of agar disc diffusion assay. Inhibition zones inhibited by fractions of n-hexane (Hx), dichloromethane (DCM), ethyl acetate (EA), n-butanol (But), aqueous (Wtr), AmpB (A) and methanol as control (M).   | 133 |
| Figure 4.20 | Bioautograms of <i>Clitoria ternatea</i> leaf fractions developed with EMW (A) and EFGW (B) eluent system. White areas indicate the reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of <i>Aspergillus niger</i> . | 135 |
| Figure 4.21 | The EFGW chromatogram after spraying with anisaldehyde-sulphuric acid.  | 136 |
| Figure 4.22 | The back view of agar disc diffusion assay. Inhibition zones inhibited by fractions of crude leaf extract (C), n-butanol (B), active spot (S) and methanol as control (M).  | 139 |
| Figure 4.23 | Bioautograms of <i>C. ternatea</i> butanol fractions and sp1 developed with EFGW eluent system. White areas indicate the reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of <i>A. niger</i> .                     | 141 |
| Figure 4.24 | The chromatogram of sp1 through non-polar column.   | 143 |
| Figure 4.25 | The chromatogram of sp1 through polar column.   | 144 |
| Figure 4.26 | The typical IR spectra of <i>C. ternatea</i> sp1.   | 146 |

## LIST OF SYMBOLS AND ABBREVIATIONS

|                     |   |
|---------------------|---|
| %                   | : Percent sign                            |
| °C                  | : Degree celcius                          |
| β                   | : Beta                                    |
| δ                   | : Delta                                   |
| γ                   | : Gamma                                   |
| <i>g</i>            | : Gravity                                 |
| κ                   | : Kappa                                   |
| σ                   | : Sigma                                   |
| μ                   | : Micro                                   |
| μ                   | : Mu                                      |
| μ <sub>1</sub>      | : Mu type 1                               |
| μ <sub>2</sub>      | : Mu type 2                               |
| 4x                  | : Microscope magnification at 4x          |
| 10x                 | : Microscope magnification at 10x         |
| 20x                 | : Microscope magnification at 20x         |
| Aδ                  | : A-delta                                 |
| ABPA                | : Allergic bronchopulmonary aspergillosis |
| <i>A. flavus</i>    | : <i>Aspergillus flavus</i>               |
| <i>A. fumigatus</i> | : <i>Aseprgillus fumigatus</i>            |
| <i>A. nidulans</i>  | : <i>Aspergillus nidulans</i>             |
| <i>A. niger</i>     | : <i>Aspergillus niger</i>                |
| AlCl <sub>3</sub>   | : Aluminium chloride                      |
| AmpB                | : Amphotericin B                          |
| ANOVA               | : One way analysis of variance            |

|   |  |
|---|--|
| ANS   | : Autonomic nervous system                         |
| A <sub>0</sub>                                  | : Absorbance of the control                        |
| ArOH  | : Aromatic ring                                    |
| A <sub>S</sub>                                  | : Absorbance of test extract solution              |
| <i>A. terreus</i>                               | : <i>Aspergillus terreus</i>                       |
| BEA   | : Benzene/ethanol/ammonium hydroxide               |
| BHT   | : Butylated hydroxytoluene                         |
| (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> O | : Diethyl ether                                    |
| CEF   | : Chloroform/ ethyl acetate/ formic acid           |
| CFU   | : Colony forming unit                              |
| CFU/mL  | : Colony forming unit per milliliter               |
| CFU/organ                                       | : Colony forming unit per organ sample             |
| CH <sub>3</sub> COOH                            | : Glacial acetic acid                              |
| CH <sub>3</sub> COONa•3H <sub>2</sub> O         | : Sodium acetate trihydrate                        |
| CLSI  | : Clinical and Laboratory Standards Institute      |
| cm  | : Centimeter                                       |
| cm <sup>-1</sup>                                | : Reciprocal centimeter (units of wavenumber)      |
| cm/s  | : Centimeter per second                            |
| CNS   | : Central nervous system                           |
| Conidio/mice                                    | : <i>Aspergillus niger</i> conidio per mice sample |
| COX-1   | : Cyclooxygenase 1                                 |
| COX-2   | : Cyclooxygenase 2                                 |
| <i>C. ternatea</i>                              | : <i>Clitoria ternatea</i>                         |
| Cu(II)  | : Copper(II)                                       |
| DNA   | : Deoxyribonucleic acid                            |

|                                      |   |
|--------------------------------------|---|
| DPPH                                 | : 2,2-diphenyl-2-picryl-hydrazyl  |
| EDTA                                 | : Ethylenediaminetetra acetic acid  |
| EFGW                                 | : Ethyl acetate/formic acid/glacial acetic acid/water                     |
| e.g.                                 | : For example   |
| ELISA                                | : Enzyme-linked immunosorbent assay                                       |
| EMEA                                 | : European Medicines Agency   |
| EMW                                  | : Ethyl acetate/methanol/water  |
| FCA                                  | : Freund's complete adjuvant  |
| FCR                                  | : Folin-Ciocalteu reagent   |
| Fe(II)                               | : Iron (II)   |
| Fe <sup>2+</sup> -TPTZ               | : Ferrous tripyridyltriazine  |
| Fe <sup>3+</sup> -TPTZ               | : Ferric tripyridyltriazine   |
| FeCl <sub>3</sub>                    | : Ferric chloride   |
| FeSO <sub>4</sub> •7H <sub>2</sub> O | : Eisen II sulfat heptahydrate  |
| FRAP                                 | : Ferric reducing antioxidant power                                       |
| FTIR                                 | : Fourier Transform Infrared Red  |
| g                                    | : Gram  |
| GC                                   | : Gas Chromatography  |
| GC-MS                                | : Gas Chromatography-Mass Spectroscopy                                    |
| GHS                                  | : Globally Harmonised System  |
| g/kg                                 | : Dose (weight of test substance in grams per unit weight of test animal) |
| GM                                   | : Galactomannan   |
| GMI                                  | : Galactomannan index   |
| GM/mL                                | : Galactomannan per milliliter  |
| GMS                                  | : Grocott's methenamine silver stain                                      |

|                                 |   |
|---------------------------------|---|
| GRAS                            | : Generally recognized as safe                    |
| h                               | : Hour  |
| H                               | : Hydrogen  |
| H <sup>•</sup>                  | : Hydrogen free radical                           |
| H <sub>2</sub> O <sub>2</sub>   | : Hydrogen peroxide                               |
| H <sub>2</sub> SO <sub>4</sub>  | : Sulphuric acid                                  |
| HAT                             | : Hydrogen atom transfer                          |
| HCl                             | : Hydrochloric acid                               |
| HOCl                            | : Hypochlorous acid                               |
| HPLC                            | : High Performance Liquid Chromatography          |
| HPTLC                           | : High Performance Thin Layer Chromatography      |
| IA                              | : Invasive pulmonary aspergillosis                |
| IASP                            | : International Association for the Study of Pain |
| IC <sub>50</sub>                | : Half maximal inhibitory concentration           |
| i.e.                            | : That is   |
| INT                             | : <i>p</i> -Iodonitrotetrazolium chloride         |
| i.p.                            | : Intraperitoneal                                 |
| IR                              | : Infrared  |
| i.v.                            | : Intravenous                                     |
| K <sub>2</sub> HPO <sub>4</sub> | : Dipotassium hydrogen phosphate                  |
| KBr                             | : Potassium bromide                               |
| KH <sub>2</sub> PO <sub>4</sub> | : potassium dihydrogen orthophosphate             |
| kV                              | : Kilovolt  |
| LC-MS                           | : Liquid Chromatography Mass Chromatography       |
| LD <sub>50</sub>                | : Median lethal oral dose                         |

|                 |   |
|-----------------|---|
| LDL             | : Low-density lipoprotein   |
| m               | : Meter   |
| MBC             | : Minimum bactericidal concentration  |
| MFC             | : Minimum fungicidal concentration  |
| MIC             | : Minimum inhibitory concentration  |
| Mice/group      | : Number of mice per group  |
| min             | : Minutes   |
| mg CE/g         | : Milligram catechin equivalents in 1 gram of sample                                      |
| mg GAE/g        | : Milligram gallic acid equivalents in 1 gram of sample                                   |
| mg/kg           | : Dose (weight of test substance in milligrams per unit weight of test animal)            |
| mg/mL           | : Concentration (weight of test substance in milligrams per volume of test concentration) |
| MHA             | : Mueller–Hinton agar   |
| mL              | : Milliliter  |
| mL/kg           | : Milliliter per kilogram   |
| mL/min          | : Gas flow rate millimeter per minute   |
| mm              | : Millimeter  |
| mm <sup>2</sup> | : Millimeter x millimeter   |
| mM              | : Millimolar  |
| mM/L            | : Millimolar / Liter  |
| mN/cm           | : MilliNewtons / centimeter   |
| mPa/s           | : milliPascal / second  |
| MRSA            | : Methicillin or multi-resistant <i>Staphylococcus aureus</i>                             |
| n               | : Sample size   |
| NaCl            | : Sodium chloride   |

|                          |  |
|--------------------------|--|
| $\text{Na}_2\text{CO}_3$ | : Sodium carbonate                                       |
| ng                       | : Nanogram   |
| NIR                      | : Near infrared  |
| NIST                     | : National Institute of Standard and Technology          |
| nm                       | : Nanometer  |
| No                       | : Number   |
| NSAIDs                   | : Non-steroidal anti-inflammatory drugs                  |
| $^1\text{O}_2$           | : Singlet oxygen   |
| $\text{O}_2$             | : Oxygen   |
| $\text{O}_2^\bullet$     | : Superoxide anion                                       |
| $\text{O}_3$             | : Ozone  |
| OD                       | : Optical density  |
| OECD                     | : Organization for Economic Co-operation and Development |
| $\text{OH}^\bullet$      | : Hydroxyl   |
| $\text{OOH}^\bullet$     | : Hydroperoxyl   |
| ORAC                     | : Oxygen radical absorbance capacity                     |
| $\text{OsO}_4$           | : Osmium tetroxide                                       |
| p                        | : Pearson  |
| PAG                      | : Peri-aqueductal gray                                   |
| PAS                      | : Periodic acid-Schiff                                   |
| PCR                      | : Polymerase chain reaction                              |
| PDA                      | : Potato dextrose agar                                   |
| PDB                      | : Potato dextrose broth                                  |
| PLC                      | : Preparative layer chromatography                       |
| p.o.                     | : Oral administration                                    |



|                |  |
|----------------|--|
| Ramp/min       | : Rate of temperature increases per minute                   |
| R <sub>f</sub> | : Retention factor   |
| RO•            | : Alkoxy radical   |
| ROO•           | : Peroxy radical   |
| ROOH           | : Lipid hydroperoxide  |
| ROS            | : Reactive oxygen species                                    |
| RSA            | : Radical scavenging activity                                |
| s              | : Seconds  |
| s.c.           | : Subcutaneous   |
| SD             | : Standard deviation   |
| SDA            | : Sabouraud dextrose agar                                    |
| SEM            | : Scanning Electron Microscopy                               |
| SET            | : Single electron transfer                                   |
| SMs            | : Secondary metabolites                                      |
| Sp1            | : Active spot 1  |
| SPE            | : Solid phase extraction                                     |
| spp.           | : Species  |
| SPSS           | : Statistical Package for the Social Sciences                |
| TEAC           | : Trolox equivalence antioxidant capacity                    |
| TLC            | : Thin Layer Chromatography                                  |
| TPTZ           | : 2,4,6-tris(2-pyridyl)-s-triazine                           |
| t <sub>R</sub> | : Retention time   |
| TRAP           | : Total radical trapping antioxidant                         |
| µg             | : Microgram  |
| µg/mL          | : Microgram of plant extract per milliliter of assay mixture |

|                               |  |
|-------------------------------|--|
| $\mu\text{L}$                 | : Microliter   |
| U/mL                          | : Unit per milliliter  |
| $\mu\text{m}$                 | : Micrometer   |
| $\mu\text{M Fe[II]}/\text{g}$ | : Micromolar ferric reducing ability in 1 g of dry weight plant material |
| $\mu\text{M}/\text{L}$        | : Micromolar per liter   |
| USFDA                         | : United States Food and Drug Administration                             |
| UV                            | : Ultraviolet  |
| UV-254nm                      | : Ultraviolet at 254 nm wavelength                                       |
| UV-365nm                      | : Ultraviolet at 365 nm wavelength                                       |
| vis.                          | : Visible  |
| VRE                           | : Vancomycin resistant <i>enterococci</i>                                |
| vs.                           | : Versus   |
| v/v/v                         | : Volume per volume per volume   |
| v/v/v/v                       | : Volume per volume per volume per volume                                |
| W                             | : Watt   |
| WHO                           | : World Health Organization  |

## LIST OF APPENDICES

- Appendix A1 Ethical clearance letter for acute toxicity studies of *C. ternatea* leaf extract.
- Appendix A2 A typical example of DPPH scavenging effect (%) calculation.
- Appendix A3 A typical example of ferric reducing power calculation.
- Appendix A4 A typical example of total phenolic content calculation.
- Appendix A5 A typical example of total flavonoid content calculation.
- Appendix A6 Ethical clearance letter for antinociceptive studies of *C. ternatea* leaf extract.
- Appendix A7 Ethical clearance letter for *in vivo* studies of *C. ternatea* leaf extract.
- Appendix A8 Raw data for acute toxicity sighting study.

## LIST OF PUBLICATIONS AND CONFERENCES

### PUBLICATIONS

1. Kamilla, L., Mansor, S. M., Ramanathan, S., & Sasidharan, S. (2009). Antimicrobial activity of *Clitoria ternatea* (L.) extracts. *Pharmacologyonline*, 1, 731-738. (Peer review journal-Scopus).
2. Kamilla, L., Mansor, S. M., Ramanathan, S., & Sasidharan, S. (2009). Effects of *Clitoria ternatea* leaf extract on growth and morphogenesis of *Aspergillus niger*. *Microscopy and Microanalysis*, 15, 366-372. ISI journal (Impact factor: 2.99).

### PUBLICATIONS IN PROGRESS

1. Kamilla, L., Ramanathan, S., Sasidharan, S., Murugaiyah, V., & Mansor, S. M. (2011). *In vivo* antifungal efficacy of *Clitoria ternatea* leaf extract against experimental aspergillosis. *Phytotherapy Research* (Manuscript submitted) Impact factor: 1.746.
2. Kamilla, L., Ramanathan, S., Sasidharan, S., & Mansor, S. M. (2011). Antinociceptive studies of *C. ternatea* leaf and root extracts, *Journal of Natural Medicine*. (Manuscript completed in progress for submission) Impact factor: 1.027.

### CONFERENCE PRESENTATION

1. Kamilla, L., Ramanathan, S., Sasidharan, S., Murugaiyah, V., & Mansor, S. M. (2009). *In vitro* antioxidant activities of *Clitoria ternatea*'s extracts, 4<sup>th</sup> Global Summit on Medicinal and Aromatic Plants, Kuching, Sarawak (Oral presentation).

## KAJIAN FARMAKOLOGI DAN FITOKIMIA *CLITORIA TERNATEA* EKSTRAK

### ABSTRAK

Dalam tesis ini, penyaringan fitokimia, antimikrob, antioksidan dan aktiviti analgesik telah dijalankan ke atas pelbagai bahagian pokok *C. ternatea* dengan menggunakan pelbagai teknik bioassai dan model eksperimental yang sesuai. Penyaringan fitokimia menunjukkan kehadiran tanin, flobatanin, flavonoid, antrakuinon, alkaloid, saponin, glikosida kardiak, minyak meruap, steroid and terpenoid. Kandungan flavonoid dan fenol dalam pelbagai bahagian tumbuhan juga telah ditentukan. Analisis menunjukkan ekstrak bunga *C. ternatea* mengandungi kandungan fenol ( $104.77 \pm 2.64$  mg asid gallik/g jisim tumbuhan) dan flavonoid ( $28.10 \pm 4.13$  mg katecin/g jisim tumbuhan) yang tinggi apabila dibandingkan dengan bahagian-bahagian lain. Hal ini telah terbukti apabila ekstrak bunga *C. ternatea* menunjukkan aktiviti antioksidan yang paling tinggi (FRAP:  $6.80 \pm 0.32$   $\mu$ M Fe(II)/g jisim tumbuhan; DPPH IC<sub>50</sub> :  $9.17 \pm 0.003$   $\mu$ g/mL) berbanding dengan bahagian-bahagian lain tumbuhan ini. Kaempferol-3-glukosida (K3G) yang merupakan sebatian flavonoid telah dikenalpasti sebagai salah satu bioaktif dalam ekstrak daun, batang dan bunga *C. ternatea*. Bioaktif ini mungkin merupakan penyumbang kepada aktiviti antioksidan. Bagi penyaringan antimikrob *in vitro*, kedua-dua ekstrak daun dan akar *C. ternatea* menunjukkan aktiviti antimikrob yang tinggi. Lebih-lebih lagi, ekstrak daun *C. ternatea* ini menunjukkan aktiviti antikulat yang bagus terhadap *Aspergillus niger* dengan nilai perencatan minimum (MIC) 0.4 mg/mL dan nilai kepekatan maut minimum (MFC) 0.8 mg/mL. Hal ini telah terbukti apabila analisis mikroskop pengimbasan elektron (SEM) telah menunjukkan perubahan morfologi yang ketara ke atas dinding hifa dan konidiofor selepas pendedahan kepada ekstrak daun *C.*

*ternatea* berbanding dengan kumpulan kawalan. Sebelum kajian analgesik dan antikulat dikaji, ketoksikan akut ekstrak daun *C. ternatea* telah dijalankan dengan menggunakan mencit. Nilai LD<sub>50</sub> ekstrak daun *C. ternatea* adalah melebihi daripada dos berat badan 2000 mg/kg yang menunjukkan ekstrak daun *C. ternatea* ini berada pada zon selamat yang tinggi. Selanjutnya, model haiwan telah digunakan untuk mengkaji aktiviti analgesik dan antikulat ekstrak daun *C. ternatea*. Kedua-dua ekstrak daun dan akar *C. ternatea* menunjukkan aktiviti analgesik yang lebih baik apabila berbanding dengan kumpulan kawalan. Namun begitu, aktiviti analgesik adalah tidak setanding dengan tikus yang di rawat dengan morfina. Dalam kajian yang lain, aktiviti *in vivo* antikulat ekstrak daun *C. ternatea* telah dikaji dengan menggunakan mencit yang telah dijangkiti dengan *A. niger*. Aktiviti antikulat ekstrak daun *C. ternatea* adalah setanding dengan amfoterisin B. Kajian fraksinasi bioaktiviti berpandu menyarankan yang aktiviti antikulat ekstrak daun *C. ternatea* mungkin disebabkan oleh aktiviti sinergisme pelbagai bioaktif yang terdapat di dalam ekstrak tersebut. Fraksi bioaktif telah dianalisis selanjutnya dengan menggunakan kromatografi gas-spektroskopi jisim (GC-MS) dan spektroskopi inframerah (FTIR). Analisis ini menunjukkan yang fraksi bioaktif ini mungkin tergolong dalam kumpulan lipid dan/ atau terpenoid (seskuiterpena).

## SOME PHARMACOLOGICAL AND PHYTOCHEMICAL STUDIES OF *CLITORIA TERNATEA* EXTRACTS

### ABSTRACT

In this thesis, detailed work was carried out to explore and determine the phytochemical screening, potential anti-infective, antioxidant and analgesic properties of *C. ternatea* plant parts using various bioassays techniques and appropriate experimental models. The initial qualitative phytochemical screening shows that *C. ternatea* plant parts contain tannin, phlobatannin, flavonoid, anthraquinone, alkaloid, saponin, cardiac glycosides, volatile oils, steroids and terpenoids. The flavonoids and phenolic content of the various plant parts were also determined in the plant parts. Analysis shows that *C. ternatea* flower extract has both high phenolic ( $104.77 \pm 2.64$  mg GAE/g) and flavonoid ( $28.10 \pm 4.13$  mg CE/g) content than other plant parts. This is evident by the fact that *C. ternatea* flower extract exhibited the highest antioxidant activity (FRAP:  $6.80 \pm 0.32$   $\mu$ M Fe(II)/g ; DPPH IC<sub>50</sub> :  $9.17 \pm 0.003$   $\mu$ g/mL) when compared to other parts of the plant. One of the bioactives identified in the flower extract was kaempferol-3-glucoside (K3G) which is a flavonoid compound. Kaempferol-3-glucoside was also found in *C. ternatea* stem and leaf. This could be one of the identified bioactives responsible for the antioxidant activity. As for the *in vitro* anti-infective screening, both leaf and root crude extracts demonstrated marked antimicrobial activities. Interestingly, the leaf extract demonstrated a remarkable antifungal activity against *Aspergillus niger* with a MIC and MFC of 0.4 and 0.8 mg/mL, respectively. This was evident by the scanning electron microscope (SEM) analysis which showed a marked morphological alteration of the *A. niger* hyphal wall and conidiophores after exposure to *C. ternatea* leaf extract when compared to control. The acute toxicity of

*C. ternatea* leaf extract was assessed in mice prior to antinociceptive and *in vivo* antifungal study. After oral administration in mice, the LD<sub>50</sub> was found to be higher than 2000 mg/kg body weight which indicated some high level of safety for *C. ternatea* leaf extract. Subsequently *C. ternatea* leaf extract was further tested for its antinociceptive and *in vivo* antifungal activities in animal models. Studies in rats showed that both *C. ternatea* leaf and root extracts demonstrated antinociceptive activity at the studied dosage regimens when compared with control but the analgesic effect was not comparable to morphine treated rats. In another study, the *in vivo* antifungal activity of *C. ternatea* leaf extract was investigated in *A. niger* infected mice. *C. ternatea* leaf extract antifungal activity was comparable to clinically used amphotericin B. Bioactivity guided fractionation studies of the *C. ternatea* leaf extract suggest that the antifungal activity could be a synergistic activity of various bioactives presence in the extract. Further gas chromatography-mass spectroscopy (GC-MS) and fourier transform infrared (FTIR) analysis of the fractions indicated these bioactives could be lipids and/or terpenoids (sesquiterpenes) group of compounds.





## CHAPTER 1

### 1.0 INTRODUCTION

Traditional medicinal practice has been known for centuries in many parts of the world for the treatment of various human ailments (Arora & Kaur, 2007). In developing countries, the World Health Organization (WHO) has estimated that 80% of the population rely almost on traditional medicine for their primary health care needs (World Health Organization, 2010). It is assumed that a major part of traditional therapy involves the use of plant extracts or their active principles (Ignacimuthu, Ayyanar, & Sivaraman, 2006). Hence, medicinal plants play a crucial role and constitute the backbone of traditional medicine (Mukherjee, 2002a).

Medicinal plants have formed an essential element of the materia medica of various formal and informal systems of medicine (Suneetha & Chandrakanth, 2006) as they have fitted the immediate personal need and are easily accessible and inexpensive (Mukherjee, 2002a). The demand for medicinal plants for medicinal purposes or as health supplements has been increasing worldwide and not to exclude, Malaysia has great potential to develop her abundant natural resources. However, the medicinal plants available have not been extensively exploited or studied (Jamal, 2006). Among the promising medicinal plant that should receive more attention is *Clitoria ternatea* Linn. which is one of the medicinal plants used as an ingredient in 'Medha Rasayana' a rejuvenating recipe for the treatment of neurological disorders in Ayurvedic traditional medicinal system (Sivaranjan & Balachandran, 1994).

*Clitoria ternatea* Linn. (*C. ternatea*) belongs to family Fabaceae and is a very well known Ayurvedic medicine used for various different ailments. It has been used for centuries as antidepressant, antistress, anxiolytic, memory enhancer, nootropic, anticonvulsant, tranquilizer, sedative agent and also to treat fever, arthritis, eye ailments, indigestion, constipation, ear-diseases and swollen joints. *C. ternatea* extracts is known to possess a wide range of pharmacological activities which includes anti-inflammatory, analgesic, antipyretic, antimicrobial, insecticidal, diuretic, antidiabetic, local anesthetic, blood platelet aggregation-inhibiting and vascular smooth muscle relaxing properties (Mukherjee, V. Kumar, N. S. Kumar, & Heinrich, 2008). Various secondary metabolites such as polyphenolic flavonoids, anthocyanin glycosides, pentacyclic triterpenoids, phytosterols and fatty acids have been reported in this plant (Mukherjee, Kumar, & Heinrich, 2007). Flavonols i.e. kaempferols, quercetin and myricetin and their glycosides have been also isolated from this plant (Kazuma, Noda, & Suzuki, 2003).

A review paper on *C. ternatea* by Mukherjee et al. (2008) has well documented various traditional and potential pharmacological uses of this plant. An evaluation of *C. ternatea* for its potential anti-inflammatory, antimicrobial, central nervous system (CNS) related effects are imperative for development of an effective natural remedy. Previously, finotin (a protein) isolated from *C. ternatea* was found to be potent inhibitor against various important plant fungal pathogens (Kelemu, Cardona, & Segura, 2004). Though the antifungal activity is not of immediate relevance to humans, nevertheless the finding indicates its possible antifungal effects. With this in view, it has prompted us to systematically evaluate and determine antimicrobial spectrum of *C. ternatea* against human pathogenic

microorganisms. Further to this, numerous studies have reported the presence of flavonoids and phenolic compounds in *C. ternatea* plant parts thus these suggest their potential applications as antimicrobial, antioxidant, anti-inflammatory, anticarcinogen, antiallergic, antiviral, immune-stimulating agents (Rice-Evans, Miller, & Paganga, 1996). Despite these activities, there were also studies that demonstrated the analgesic activity of methanolic *C. ternatea* roots extract using acetic-acid induced writhing test and ethanolic *C. ternatea* aerial extracts (Parimaladevi, Boominathan, & Mandal, 2003; Kulkarni, Pattanshetty, & Amruthraj, 1988) in rats.

As of to date not much work was carried out on the antimicrobial activity of various *C. ternatea* plant extracts on human pathogenic microorganism, while studies on antioxidant activity was limited only to water extract of *C. ternatea* plant parts. In addition, analgesic activity of various *C. ternatea* plant parts crude extracts have been also documented but using limited experimental models. Therefore in this thesis, detailed work was undertaken to explore and determine the potential toxicology, anti-infective, antioxidant and analgesic properties of *C. ternatea* plant parts using various bioassays techniques and appropriate experimental models. In this thesis, the chemical constituents responsible for its antifungal activity was isolated and identified.

## 1.1 Objectives

The objectives of the work carried out in this thesis are as follows:

- To obtain various crude extracts from *C. ternatea* leaves, stems, flowers, seeds and roots by means of maceration extraction method.
- To conduct qualitative phytochemical, antimicrobial and antioxidant assays on various crude extracts of *C. ternatea* leaf, stem, flower, seed and root.
- To evaluate the antinociceptive activities of *C. ternatea* leaf and root extracts using hot plate, tail-flick and formalin test models.
- To conduct oral acute toxicity in mice using *C. ternatea* leaf extract.
- To perform Scanning Electron Microscopy (SEM) and *in vivo* studies of *C. ternatea* leaf extract against *Aspergillus niger*.
- To identify the antifungal active fraction(s) from *C. ternatea* leaf extract.

## CHAPTER 2

### 2.0 LITERATURE REVIEW

#### 2.1 Herbal medicine

Plants, parts of plants and isolated phytochemicals have been used since ancient times for prevention and treatment of various health ailments (Sahoo, Machikanti, & Dey, 2010). Plants still contribute significantly to health care sector, in spite of the great advances observed in modern medicines in recent decades (Calixto, 2000). Plants may be defined as food, functional food, dietary supplement or as herbal medicine (Sahoo et al., 2010). Herbal medicines include herbs, herbal materials, herbal preparations and finished herbal products that contain active ingredients of plant parts or other plant materials or combinations (World Health Organization, 2010). Worldwide, it is estimated that 25% of the drugs prescribed are derived from plants. Besides this, 11% of the total 252 drugs in WHO's essential medicine list is exclusively of plant origin (Rates, 2001).

Herbal drugs can be categorized into three types based on the nature of their active metabolites. The first category of plant drugs are usually simple botanicals employed in their crude form. Examples are opium, belladonna, aloe and cinchona. The second category of herbal drugs is represented by the active constituents (pure molecules) isolated after the processing of plant extracts. Some of the prominent examples are reserpine from *Rauvolfia*, quinine from *Cinchona* and taxol from *Taxus* species. The third category of herbal drugs is drugs with acute and chronic toxicity data available. Examples are mineralo-herbal drug Amlena and green tea extract

(Veregen) (Iwu, Duncan, & Okunji, 1999; Chandra, Sachan, Ghosh, & Kishore, 2010; Wu, Ghantous, & Birnkrant, 2008).

WHO (2003) classified the herbal drugs into four categories such as indigenous herbal medicines, herbal medicine in systems, modified herbal medicines and imported products with an herbal medicine base. Indigenous herbal medicines are used in local community and are well known in terms of their composition, treatment and dosage. Herbal medicines in systems (Ayurveda, Unani and Siddha) have been in use for a long time. Modification of indigenous herbal medicine or herbal medicines in systems in terms of shape or form, dosage form, mode of administration, herbal medicinal ingredients, methods of preparation and medical indications represents modified herbal medicines.

In developing countries, WHO has estimated that the 80% of the population rely almost on traditional medicine for their primary health care needs. Herbal plants play a crucial role and constitute the backbone of traditional medicine (Mukherjee, 2002a). The demand for medicinal plants for medicinal purposes or as health supplements has been increasing worldwide and not to exclude, Malaysia has great potential to develop her abundant natural resources. However, the medicinal plants available herein have not been extensively exploited or studied (Jamal, 2006).

## **2.2 Plant introduction**

### **2.2.1 *Clitoria ternatea***

*Clitoria ternatea* Linn, is a very renowned Ayurvedic medicine used to treat various ailment. *C. ternatea* belongs to family Fabaceae. It is commonly known as butterfly pea, conch flower, shankapushpi and bunga telang. In Indian traditional medicine, it is known as Aparajit (Hindi), Aparajita (Bengali) and Kankattan (Tamil). Initially, *C. ternatea* is a native of the Caribbean, Central America and Mexico and currently it is well distributed in India subcontinent, Phillipines, Malaysia and other tropical Asian countries, South and Central America, Madagascar and Caribbean (Mukherjee et al., 2008).

The scientific name of the genus was derived from Greek kentron, a spur, prickle, sharp point, the center, and sema, a signal, referring to the spurred standard petal (Austin, 2004). Meanwhile, its species name was named after the island of Ternata in Moluccaa archipelago (Mukherjee et al., 2008).

### **2.2.2 Botany and pharmacognosy of *C. ternatea***

*C. ternatea* (Figure 2.1) is an ornamental perennial climber which climbs up to 2-3 m in height, grows wild and also in gardens. It bears conspicuous blue or white flowers resembling a conch-shell. Though it is presumably of American origin, today it is cultivated and naturalized throughout the humid tropics of the old and new world below 1600 m elevation (Morton, 1981).



The plant possesses imparipinnate leaves consisting of five to seven leaflets, 6-13 cm long. The leaflets are oblong or ovate, 2-5 cm long and subcoriaceous, rubiaceous stomata with wavy cell walls are present on both upper and lower epidermis of the leaflets (Mukherjee et al., 2008).

The plant bears papilionaceous, axillary, solitary flowers. The flowers are available in white or bright blue in colour with a yellow or orange center (Figure 2.2). *C. ternatea* pods are flat, nearly straight, sharply beaked and are 5-10 cm long. Each pod can bear 6-11 seeds. The seeds are yellowish-brown or blackish in color and subglobose or oval in shape (Mukherjee et al., 2008).

The *C. ternatea* root system consists of a fairly stout taproot with few branches and many slender lateral roots. The thick horizontal root can grow up to more than 2 m long, bears one to several purplish, glaucous, wiry stems. The root is woody, cream white with a few lenticels united to form transverse cracks. The fresh root is slightly bitter and acrid in taste (Mukherjee et al., 2008).




Figure 2.1: *C. ternatea* Linn plant.



Figure 2.2: *C. ternatea* Linn flower in blue colour.

### **2.2.3 Traditional uses of *C. ternatea***

*C. ternatea* has been used for centuries in traditional Ayurvedic system of medicine to treat several diseases. *C. ternatea* has been used as an ingredient in ‘Medhya Rasayana’ a rejuvenating recipe used for treatment of neurological disorders and strengthens a person’s intellect. In Ayurveda, the drug ‘Sankhapushpi’ consists of the roots and seeds of *C. ternatea* and is used as a ‘tonic of the nerves’, alterative and laxative (Mukherjee et al., 2008).

The roots and leaves are used in the treatment of a number of ailments including body aches, infections, urinogenital disorders, and as an anthelmintic and antidote to animal stings. In addition, the roots have an acrid and bitter taste and are credited with diuretic, purgative and laxative properties. The root is used in the treatment of various diseases, like indigestion, constipation, fever, arthritis and eye ailments. It is also employed in cases of ascetics, enlargement of the abdominal viscera, sore throat, skin diseases and chronic bronchitis. The decoction or powder of the root is given in rheumatism, and ear-diseases (Mukherjee et al., 2008).

Powdered seeds are mixed with ginger and given as laxative, the action, however, is accompanied by gripping in lower abdomen. The seeds are considered for colic, dropsy and enlargement of abdominal viscera; they are also used in swollen joints. The root, stem and flower are recommended for the treatment of snakebite and scorpion sting in India (Mukherjee et al., 2008).

#### **2.2.4 Other uses**

*C. ternatea* is a highly palatable forage legume generally preferred by livestock over other legumes. It exhibits excellent re-growth after cutting or grazing within short period of time and produce high yields. It is grown with tall grasses for rotational grazing, hay or silage. It is grown either alone or with other perennial grasses in Uttar Pradesh, Gujarat, Maharashtra, Madhya Pradesh, Andhra Pradesh, Punjab, Rajasthan, Tamilnadu and Karnataka in India. Besides suppressing many perennial weeds, it enriches the soil by fixing nitrogen. It is also used as drought-resistant pasture in arid and semi-arid regions (Mukherjee et al., 2008).

Butterfly pea is also used as a cover crop and green manure. It is also grown as ornamental plant due to its attractive flower colours (Kalamani & Michael, 2003). In Kerala (India) and Philippines, the young shoots, leaves, flowers and tender pods are eaten as vegetable. In Malaysia, the leaves are traditionally employed to impart a green colour to food and the flowers to impart a bright blue colour to rice cakes (Mukherjee et al., 2008). The medicinal potential of this use in Malaysian traditional practice warrants investigation.

#### **2.2.5 Pharmacological activities of *C. ternatea***

*C. ternatea* has been widely screened for various pharmacological activities. It has been documented for its neuropharmacological actions such as nootropic, antistress, antidepressant, anticonvulsant, enhancing acetylcholine content, anxiolytic, tranquilizing and sedative activities which justify its use in CNS diseases in Ayurvedic system of medicine. It has antimicrobial, antipyretic, anti-inflammatory, analgesic, diuretic, local anesthetic, antidiabetic, insecticidal, blood platelet

aggregation inhibiting and vascular smooth muscle relaxant properties (Mukherjee et al., 2008). The various reported pharmacological activities of *C. ternatea* (Table 2.1) have been summarized below.

Table 2.1: Pharmacological activities of *C. ternatea* Linn. (Source: Mukherjee et al., 2008).

| Plant part             | Extract/compound  | Activity  |
|------------------------|---|---|
| Roots and aerial parts | Aqueous extract, alcoholic extract                                | Learning and memory enhancing, enhancement of acetylcholine content.  |
| Roots and aerial parts | Alcoholic extract, methanol extract                               | Nootropic activity, anxiolytic, anxiolytic activity, antidepressant activity, tranquilizing property, sedative activity, anticonvulsant activity, and antistress activity |
| Flowers                | Anthocyanins (Ternatin A1, A2, B1, B2, D1, and D2)                | Blood platelet aggregation-inhibiting and vascular smooth muscle relaxing activities.   |
| Roots, aerial part     | Methanol extract, alcoholic extract                               | Antipyretic activity  |
| Roots                  | Methanol extract  | Anti-inflammatory and analgesic activity  |
| Seeds                  | Finotin<br>Flavonol glycoside from ethyl acetate soluble fraction | Antimicrobial activity  |
| Flowers                | Ethanol extract   | Antidiabetic activity   |
| Seeds                  | Finotin   | Insecticidal activity   |
| Roots                  | Alcoholic extract   | Diuretic activity in dogs   |
| Aerial part            | Alcoholic extract   | Local anesthetic effect   |

Though the pharmacological activities are thoroughly documented but the bioactives responsible for its pharmacological activities are still lacking. Studies on the absorption and disposition of this bioactives in preclinical and clinical trials are imperative (Mukherjee et al., 2008). Therefore *C. ternatea* merits further phytochemical, pharmacological and clinical investigations for development of therapeutically effective lead compounds or standardized extracts. In this thesis, the phytochemical, toxicity, antioxidant, analgesic and antimicrobial investigation were carried out for *C. ternatea*.

### **2.3 Quality control of extracts**

Herbal extracts are in great demand for primary healthcare in developed as well as developing countries. This is because of their extensive biological activities, lesser cost and high safety margins. The most important challenges faced by herbal extracts formulations arise because of their lack of standardization (Palav & D'mello, 2006). Various factors such as the age of the plant, part of the plant used, time of harvest, soil conditions, weather conditions, extraction and drying methods, type of solvents used, etc. greatly affects the quality, composition and bioactivity of the herbal extracts (Hendriks, Juarez, Bont, & Hall, 2005). Since these factors affect the end composition and consistency of the finished product, the standardization and quality control of the herbal extracts are required.

With the tremendous growth of herbal extracts, the health authorities and the public are concern on the quality control of herbal extracts used for treatment (Fan, Cheng, Ye, Lin, & Qian, 2006). The herbal extracts have distinctive characteristics from synthetic drugs in which the herbal extracts contain more than one active compound and the active principle is frequently unknown (Sahoo et al., 2010). Currently, the analysis of one or more selected marker compounds is used to predict the quality of herbal extracts. Ideally, the marker compounds could be responsible for the efficacy and activity of the herbal extract. However, the selected marker compounds that are often chemical characteristics of the herb may not be related to the bioactivity of the herb. Furthermore, the synergistic effect of several compounds may also contribute to the bioactivity of certain plant. The common practice of using one marker compound neglects the synergistic effect. As an outcome, the marker-based approach is found to be incomplete and unsatisfactory method for quality

control of herbal materials (Hendriks et al., 2005). Liang, Xie, & Chan (2004) have stated that this kind of determination does not give a complete picture of a herbal product because multiple constituents are usually responsible for its therapeutic effects.

Quality control of herbal preparations is the requirement of credible clinical trials. As stated in the draft guidelines by United States Food and Drug Administration (USFDA) and The European Agency for the Evaluation of Medicinal Products, various aspects of analysis must be performed for the purpose of certification of herbal preparations (Ong, 2004). The standardization methods should take into consideration all aspects that contribute to the quality of herbal drugs. The methods include correct identity of the sample, organoleptic evaluation, pharmacognostic evaluation, volatile matter, quantitative evaluation (ash values, extractive values), phytochemical and biological activity evaluation. The herbal preparations should also be tested for the presence of xenobiotics, microbial contaminations, toxicity testing, pesticides, arsenic and heavy metals contents (Rajani & Kanaki, 2008; Mukherjee, 2002b).

Among the various quality control methods, the chromatographic fingerprinting has gained a lot of attention recently. Various bodies like WHO, USFDA, European Medicines Agency (EMA), German Commission E, British Herbal Medicine Association, Indian Drug Manufacturers and others have accepted the usage of chromatographic fingerprinting to assess and standardize the herbal medicines (Fan et al., 2006). Chromatographic fingerprinting is a chromatogram that represents the chemical characteristics or pattern of a herbal extract (Cheng, Chen, &

Tong, 2003). The chemical profiling is a versatile technique and is of good use in standardization method (Mukherjee, 2002e). The common analytical techniques used are Thin Layer Chromatography (TLC), High Performance Liquid Chromatography (HPLC), Gas Chromatography-Mass Spectroscopy (GC-MS), Liquid Chromatography Mass Chromatography (LC-MS), near infrared (NIR) and spectrophotometer. A chemical fingerprint by hyphenated chromatography is used as the primary tool for quality control of herbal medicines (Liang et al., 2004) and serve as guideline to the phytochemical profile of the drug in ensuring the quality (Rajani & Kanaki, 2008). Also, the full herbal product can be regarded as the active compound (Liang et al., 2004). Chromatographic fingerprinting has potential to determine the identity, authenticity and batch-to-batch consistency of herbal medicines. Generally, samples with similar chromatographic fingerprint have similar properties (Fan et al., 2006). The chromatographic techniques enable rapid, reproducible and efficient semiquantitative and quantitative analysis of the chemical constituents in complex mixtures (Rajani & Kanaki, 2008).

## **2.4 Phytochemistry**

Phytochemistry is termed as plant chemistry. The phytochemistry studies are essential for various research disciplines such as plant physiology, plant biochemistry, chemosystematics (often referred to as chemotaxonomy), plant biotechnology and pharmacognosy (Hajnos, Sherma, & Kowalska, 2008). Phytochemistry studies are concerned with a variety of organic substances (primary and secondary metabolites) present in plant and deal with the chemical structures of these substances, their biosynthesis, turnover, metabolism, natural distribution and biological function (Harborne, 1973a).



Plants are biosynthetic producer of chemical substances such as primary and secondary metabolites (Nyiredy, 2004). Primary metabolites include amino acids, simple sugars, lipids and nucleic acids which are necessary for cellular processes and are found in all plant species (Wink, 2006; Zwenger & Basu, 2008). Secondary metabolites (SMs) differ between species and occur in mixtures. Unlike primary metabolites, SMs are not essential for energy metabolism and life but they play an important role for the ecological fitness and survival of the plants (Wink, 2006). Plant SMs are usually categorized according to their biosynthetic pathways. Phenolics, terpenes and steroids, and alkaloids are the three large molecule families that are generally considered (Bourgaud, Gravot, Milesi, & Gontier, 2001). Other SMs include lignins, flavonoids, amino acid derivatives, organic acids, polyketids and sugar derivatives (Nyiredy, 2004).

Plants SMs serve important biological and ecological roles mainly as chemical messengers and defensive compounds (Jones & Kinghorn, 2005). These molecules are able to protect plants from pathogens (phytoalexins), therefore expressed as antibiotic, antifungal and antiviral. They also act as toxic or anti-germinative for other plants (allelopathy) (Bourgaud et al., 2001). Notably, SMs constitute important ultraviolet (UV) absorbing compounds, thus preventing serious leaf damage from the light (Li, Ou-Lee, Raba, Amundson, & Last, 1993).

Plant SMs have been used in traditional medicines for centuries. Currently, SMs are used in pharmaceuticals, cosmetics, fine chemicals and also in nutraceuticals (Bourgaud et al., 2001). In western countries, studies have shown that 25% of the

molecules used in pharmaceutical industry are of natural plant origin (Payne, Bringi, Prince, & Shuler, 1991).

#### **2.4.1 Sample selection, collection and identification**

In drug discovery from plants, four standard approaches are available for selecting plants: (1) follow-up of ethnomedicine or traditional uses of plants used as food, medicine, or poison based on literature review or interviews, (2) random or systematic collection of a biodiverse set of plant samples, typically from an ecological region that is comparatively uncharted as regard to secondary metabolite production, (3) the selection of species based on phylogenetic relationship to a species known to produce a compound or compound class of interest, (4) follow up of species based on reports of biological activity in the literature (Jones & Kinghorn, 2005). A fifth, non-systematic approach is serendipity, where plant is selected based on ethnomedical use, but the bioactivity of the plant is new and unexpected (Cos, Vlietinck, Berge, & Maes, 2006).

In phytochemical analysis, the botanical identity of the plants studied should be authenticated to identify and confirm the plant identity (Harborne, 1973a). The voucher specimens (which include reproductive organs, when feasible) should be deposited in the herbarium of major institutions. The identity of the material should include observations such as its habitat, local uses of the species, microenvironment (e.g. shaded vs. sunny location), overall state of the plant health, reproductive stage and also other information that may be useful for future investigations (Jones & Kinghorn, 2005).

## **2.4.2 Extraction of plant constituents**

The most crucial step in drug discovery is processing of the plant material. During the preparation of the extract, careful measurements must be adopted to ensure the potentially active constituents are not lost, destroyed or altered. Extraction procedures such as maceration, percolation and infusion are the traditional techniques used for the extraction of medicinal plants (Cos et al., 2006). The sole purpose of such basic extraction procedures is to obtain the therapeutically desired portion and eliminate the inert material by treatment with a selective solvent known as menstruum (Singh, 2008). In pharmaceutical industry, extraction techniques such as maceration, infusion, percolation, digestion, decoction, hot continuous extraction (Soxhlet), aqueous-alcoholic extraction by fermentation, counter-current extraction, microwave-assisted extraction, ultrasound extraction (sonication) and supercritical fluid extraction are generally used (Handa, 2008).

### **2.4.2 (a) Maceration extraction**

Specific extraction procedures are usually employed to produce enriched extracts when a particular phytochemical constituent or compound class is targeted to be extracted for an investigation (Jones & Kinghorn, 2005). In this thesis, the maceration extraction method was used. Maceration is the extraction process of drug/plant extracts with a solvent with several daily shakings or stirrings at room temperature. Maceration is one of the most widely used extraction method and can be carried out with small samples (Mukherjee, 2002c).

The maceration system is static except during occasional shaking. The occasional shaking removes the concentrated solution accumulating around the

surface of the particles and mixes it with the rest of the menstruum whereby it brings fresh menstruum to the particle surface for further extraction. The shaking also assists in diffusion. A closed system is used as it prevents the evaporation of menstruum over a prolonged period and this avoids batch-to-batch variation (Sambamurthy, 2005).

#### 2.4.2 (b) Types of solvent

Interactions between the solvent and solute can be assessed by several indicators for example the dipole moment, polarity index, viscosity and surface tension (Lalman & Badley, 2004). The chemical properties of frequently used solvent for extraction purpose are tabulated in Table 2.2.

Table 2.2: Chemical properties of solvents.

| Types of solvent  | Polarity index <sup>a</sup> | Surface tension (mN/cm) <sup>b</sup> | Viscosity (mPa/s) <sup>c</sup> | Dipole moment (Debye) <sup>d</sup> |
|-------------------|-----------------------------|--------------------------------------|--------------------------------|------------------------------------|
| <i>n</i> -Hexane  | 0                           | 17.9                                 | 0.30                           | 0                                  |
| <i>n</i> -Butanol | 4.0                         | 24.2                                 | 0.41                           | 1.521                              |
| Chloroform        | 4.1                         | 26.5                                 | 0.53                           | 1.155                              |
| Ethyl acetate     | 4.4                         | 23.1                                 | 0.43                           | 1.831                              |
| Methanol          | 5.1                         | 22.3                                 | 0.54                           | 1.621                              |
| Ethanol           | 5.2                         | 21.9                                 | 1.08                           | 1.550                              |
| Water             | 9.0                         | 72.8                                 | 0.89                           | 1.870                              |

<sup>a</sup> Retrieved from Gupta et al., 1997 and Synder 1974

<sup>b</sup> Retrieved from Markom et al., 2007

<sup>c</sup> Retrieved from Synder 1974

<sup>d</sup> Retrieved from Sheng et al., 2011

The dipole moment measures the polarity of a molecule as a net sum of the dipole moments of its polar bonds (Sheng, Vannela, & Rittman, 2011). The interaction between the solvent and solute also resulted in the overall increase of dipole moment for the solution (Markom, Hasan, Daud, Singh, & Jahim, 2007).

The polarity index is defined as the measure of the ability of the solvent to interact with various polar test solutes, and it increases with solvent polarity. The higher polarity index value demonstrates their stronger capability do dissolve more polar solutes. Vice versely, solvents with lower polarity index value exhibits weaker ability in interacting with polar solutes. Solvents with low viscosity have low density and high diffusivity, and can easily diffuse into the pores of the plant materials (Sheng et al., 2011). Temperature is another important factor that contributes to the interaction between the solvent and solute. High temperature breaks the solute-matrix, reduces the viscosity and surface tension and therefore improves the extraction yield (Markom et al., 2007). However, higher temperatures are avoided as it can cause degradation of thermolabile compounds (Sheng et al., 2011).

### **2.4.3 Purification of plant constituents**

Purification of the extract is the next step and a vital one in the sample preparation after the extraction process. The existing purification method includes analytical and preparative process. In analytical purification, the most widely used method is the solid-phase extraction (SPE) meanwhile in preparative purification, the liquid-liquid extraction method is used (Nyiredy, 2004). As for liquid-liquid extraction method extraction is based on the partition between the immiscible solvents (Nyiredy, 2004). The extract usually dissolved in water is mixed with another solvent which does not mix with the aqueous phase. The plant constituents solubilise in each of the phases and after a time, equilibrium between the phases is reached. The solvent added is replaced with another immiscible solvent to the aqueous phase (Houghton & Raman, 1998b). The frequently used immiscible phases include diethyl ether/water, chloroform/water, ethyl acetate/water and dichloromethane/water (Nyiredy, 2004).

Vigorous mixings of the two phases in a stoppered separating funnel can shorten the time taken for the equilibrium to be achieved (Houghton and Raman, 1998b). In this thesis, the liquid-liquid extraction method was used to purify the *C. ternatea* constituents.

#### **2.4.4 Separation and identification of plant constituents**

In search of plant active constituents, various combinations of separation methods such as extraction, purification and chromatography are essential. The first two methods belong to sample preparation meanwhile the chromatographic methods are used to evaluate the qualitative and quantitative analysis, as well as for isolation purposes (Nyireddy, 2004). In this thesis, bioassay guided TLC was used to separate and purify the bioactive fraction. Subsequently the GC-MS and Fourier Transform Infrared Red (FTIR) were used to identify the purified bioactive fraction.

##### **2.4.4 (a) Thin Layer Chromatography (TLC)**

TLC is one of the most extensively used chromatography methods in an organic laboratory (David, 2001). The TLC is a quick method that would separate small quantity of compounds (Raaman, 2008a). TLC is simple, low in cost, flexible and allows multiple detections. It is also used as an ideal screening method in chemical and biological analysis, provides identification and qualitative results and determines adulteration together with quantitative and semi-quantitative determination. Furthermore, TLC is the only technique in which all the components of the sample can be displayed in the chromatogram. In contrast, Gas Chromatography (GC) is selective and not all of the compounds in the sample are included in the display (Marston, 2007).

TLC is classified as solid-liquid chromatography since a solid is used as the stationary phase and a liquid as the mobile phase. The separation of compounds in a sample involves the adsorption principle, thus TLC is regarded as adsorption chromatography and the principle is exactly the same as column chromatography. The compounds are separated due to their different adsorption strengths to the adsorbent (David, 2001).

In simple terms, the mobile phase solvents desorb and dissolve the compounds from their binding to the adsorbent and carry the compounds upwards, in the direction of the movement of the solvent. Thus the compounds move due to the dynamic adsorption and desorption (David, 2001). Compounds which have great affinity for the mobile phase is desorbed and moved from the stationary phase and deposited near the solvent front whereas compounds with a lower affinity is deposited nearer to the origin (R. J. Hamilton & S. Hamilton, 1987). The distance travelled by the compounds are measured and reported as  $R_f$  value where

$$R_f = \frac{\text{Distance moved by the compound}}{\text{Distance moved by the solvent front}}$$

#### **2.4.4 (b) Gas Chromatography-Mass Spectroscopy (GC-MS)**

GC-MS is an essential analytical technique used for qualitative and quantitative analysis of solid, liquid and gaseous samples (Raaman, 2008b) and also to characterize and identify the volatile organic compounds in complex mixtures (Zhu et al., 2009). This technique also provides information about the structure of a wide variety of complex molecular structure, the isotopic ratios of atoms in samples and the structure and composition of solid surfaces. In general, the samples injected are

converted into gaseous ions and then separated on the basis of their mass-to-charge ratio (Raaman, 2008b).

In gas chromatography, the sample is vapourised and injected onto the head of the chromatographic column (Raaman, 2008b). The column contains a liquid stationary phase which is either coated on to the walls of a narrow column (as in capillary column GC) or on to small particles of an inert, solid material which is packed in wider column (packed-column GC) (Houghton & Raman, 1998c). The samples are transported through the column by the flow of an inert gas (often nitrogen, helium and argon) mobile phase. The components of the mixtures are distributed between a gas and a liquid phase (Raaman, 2008b) and separated due to differences in their relative affinities for the liquid and gaseous phases (Houghton & Raman, 1998c). The rate of migration of the components is determined by how much of it is distributed into the gas phase. The higher the percentage of material in the gas phase, the faster it will migrate. For example, a component that distributes itself 100% into the gas phase will migrate at the same rate as the flowing gas. On the other hand, a species that distributes 100% into the stationary phase, will not migrate at all. Components that distribute themselves partly in both phases will migrate at an intermediate rate (Raaman, 2008b).

The primary criterion for the peaks identification is the retention time ( $t_R$ ) which is termed as the time between sample injection and an analyte peak reaching a detector at the end of the column (Hu et al., 2006; Raaman, 2008b). The chromatographic detector (mass spectrometer) provides additional data for the